Sebastian Havervall

About me
Publications
Public outreach and news

About me

* Consultant at Danderyd hospital, Stockholm, Sweden
* Specialist in Internal Medicine and Gastroenterology and Hepatology
* PhD-student in Thålin research group

Articles

Article: THE LANCET REGIONAL HEALTH - EUROPE. 2024;38:100872

Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023.

Aguilera K; Bladh O; Marking U; Norin NG; Rihani A; Ujvari D; Ning FC; Klingström J; Havervall S; Åberg M; Blom K; Alm JJ; Thålin C
Article: FRONTIERS IN IMMUNOLOGY. 2024;15:1346749

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.

Bladh O; Aguilera K; Marking U; Kihlgren M; Greilert Norin N; Smed-Sörensen A; Sällberg Chen M; Klingström J; Blom K; Russell MW; Havervall S; Thålin C; Åberg M
Article: NATURE COMMUNICATIONS. 2023;14(1):1577

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.

Marking U; Havervall S; Norin NG; Bladh O; Christ W; Gordon M; Ng H; Blom K; Phillipson M; Mangsbo S; Alm JJ; Smed-Sörensen A; Nilsson P; Hober S; Åberg M; Klingström J; Thålin C
Article: RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS. 2023;7(3):100124

Tissue factor activity of small and large extracellular vesicles in different diseases.

Sachetto ATA; Archibald SJ; Hisada Y; Rosell A; Havervall S; van Es N; Nieuwland R; Campbell RA; Middleton EA; Rondina MT; Thålin C; Mackman N
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;96(5):e13215

Impact of monocyte-related modulators and kidney function on mortality in hospitalized patients with COVID-19.

Sendic S; Mansouri L; Havervall S; Thålin C; Lundahl J; Jacobson SH
Article: CYTOKINE. 2022;159:156020

IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden.

Ziegler L; Lundström A; Havervall S; Thålin C; Gigante B
Article: BMC NEPHROLOGY. 2022;23(1):299

"Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19".

Mansouri L; Sendic S; Havervall S; Thålin C; Jacobson SH; Lundahl J
Article: EMBO MOLECULAR MEDICINE. 2022;14(8):e15230

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.

Monteil V; Eaton B; Postnikova E; Murphy M; Braunsfeld B; Crozier I; Kricek F; Niederhöfer J; Schwarzböck A; Breid H; Devignot S; Klingström J; Thålin C; Kellner MJ; Christ W; Havervall S; Mereiter S; Knapp S; Sanchez Jimenez A; Bugajska-Schretter A; Dohnal A; Ruf C; Gugenberger R; Hagelkruys A; Montserrat N; Kozieradzki I; Hasan Ali O; Stadlmann J; Holbrook MR; Schmaljohn C; Oostenbrink C; Shoemaker RH; Mirazimi A; Wirnsberger G; Penninger JM
Article: IMMUNITY INFLAMMATION AND DISEASE. 2022;10(4):e595

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Laurén I; Havervall S; Ng H; Lord M; Pettke A; Greilert-Norin N; Gabrielsson L; Chourlia A; Amoêdo-Leite C; Josyula VS; Eltahir M; Kerzeli I; Falk AJ; Hober J; Christ W; Wiberg A; Hedhammar M; Tegel H; Burman J; Xu F; Pin E; Månberg A; Klingström J; Christoffersson G; Hober S; Nilsson P; Philipson M; Dönnes P; Lindsay R; Thålin C; Mangsbo S
Article: VACCINES. 2022;10(3):359

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.

Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingström J; Gordon M; Åberg M; Thålin C
Article: NEW BIOTECHNOLOGY. 2022;66:46-52

A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.

Mravinacova S; Jönsson M; Christ W; Klingström J; Yousef J; Hellström C; Hedhammar M; Havervall S; Thålin C; Pin E; Tegel H; Nilsson P; Månberg A; Hober S
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2022;11(4):e1388

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.

Havervall S; Marking U; Greilert-Norin N; Gordon M; Ng H; Christ W; Phillipson M; Nilsson P; Hober S; Blom K; Klingström J; Mangsbo S; Åberg M; Thålin C
Article: PLOS ONE. 2022;17(1):e0262169

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.

Havervall S; Jernbom Falk A; Klingström J; Ng H; Greilert-Norin N; Gabrielsson L; Salomonsson A-C; Isaksson E; Rudberg A-S; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Christ W; Olausson M; Hedhammar M; Tegel H; Mangsbo S; Phillipson M; Månberg A; Hober S; Nilsson P; Thålin C
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):72-80

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson A-C; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
Article: JOURNAL OF MEDICAL VIROLOGY. 2021;93(10):5908-5916

Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.

Lundström A; Ziegler L; Havervall S; Rudberg A-S; von Meijenfeldt F; Lisman T; Mackman N; Sandén P; Thålin C
Article: SCIENTIFIC REPORTS. 2021;11(1):18025

Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma.

Zenlander R; Havervall S; Magnusson M; Engstrand J; Ågren A; Thålin C; Stål P
Article: EBIOMEDICINE. 2021;70:103523

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.

Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson A-C; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
Article: SCIENTIFIC REPORTS. 2021;11(1):14015

An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism.

Razzaq M; Iglesias MJ; Ibrahim-Kosta M; Goumidi L; Soukarieh O; Proust C; Roux M; Suchon P; Boland A; Daiain D; Olaso R; Havervall S; Thalin C; Butler L; Deleuze J-F; Odeberg J; Morange P-E; Trégouët D-A
Article: NATURE COMMUNICATIONS. 2021;12(1):3695

Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2.

Roxhed N; Bendes A; Dale M; Mattsson C; Hanke L; Dodig-Crnković T; Christian M; Meineke B; Elsässer S; Andréll J; Havervall S; Thålin C; Eklund C; Dillner J; Beck O; Thomas CE; McInerney G; Hong M-G; Murrell B; Fredolini C; Schwenk JM
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2021;41(2):878-882

Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report.

Rosell A; Havervall S; von Meijenfeldt F; Hisada Y; Aguilera K; Grover SP; Lisman T; Mackman N; Thålin C
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2021;41(2):988-994

Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.

Ng H; Havervall S; Rosell A; Aguilera K; Parv K; von Meijenfeldt FA; Lisman T; Mackman N; Thålin C; Phillipson M
Article: FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2021;11:795026

A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation.

Heber S; Pereyra D; Schrottmaier WC; Kammerer K; Santol J; Rumpf B; Pawelka E; Hanna M; Scholz A; Liu M; Hell A; Heiplik K; Lickefett B; Havervall S; Traugott MT; Neuböck MJ; Schörgenhofer C; Seitz T; Firbas C; Karolyi M; Weiss G; Jilma B; Thålin C; Bellmann-Weiler R; Salzer HJF; Szepannek G; Fischer MJM; Zoufaly A; Gleiss A; Assinger A
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1312

Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.

Hober S; Hellström C; Olofsson J; Andersson E; Bergström S; Jernbom Falk A; Bayati S; Mravinacova S; Sjöberg R; Yousef J; Skoglund L; Kanje S; Berling A; Svensson A-S; Jensen G; Enstedt H; Afshari D; Xu LL; Zwahlen M; von Feilitzen K; Hanke L; Murrell B; McInerney G; Karlsson Hedestam GB; Lendel C; Roth RG; Skoog I; Svenungsson E; Olsson T; Fogdell-Hahn A; Lindroth Y; Lundgren M; Maleki KT; Lagerqvist N; Klingström J; Da Silva Rodrigues R; Muschiol S; Bogdanovic G; Arroyo Mühr LS; Eklund C; Lagheden C; Dillner J; Sivertsson Å; Havervall S; Thålin C; Tegel H; Pin E; Månberg A; Hedhammar M; Nilsson P
Article: PLOS ONE. 2021;16(9):e0258041

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses.

Mangsbo SM; Havervall S; Laurén I; Lindsay R; Jernbom Falk A; Marking U; Lord M; Buggert M; Dönnes P; Christoffersson G; Nilsson P; Hober S; Phillipson M; Klingström J; Thålin C
Article: RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS. 2021;5(1):132-141

Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.

von Meijenfeldt FA; Havervall S; Adelmeijer J; Lundström A; Rudberg A-S; Magnusson M; Mackman N; Thalin C; Lisman T
Article: NATURE COMMUNICATIONS. 2020;11(1):5064

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.

Rudberg A-S; Havervall S; Månberg A; Jernbom Falk A; Aguilera K; Ng H; Gabrielsson L; Salomonsson A-C; Hanke L; Murrell B; McInerney G; Olofsson J; Andersson E; Hellström C; Bayati S; Bergström S; Pin E; Sjöberg R; Tegel H; Hedhammar M; Phillipson M; Nilsson P; Hober S; Thålin C
Show more

All other publications

Letter: LANCET INFECTIOUS DISEASES. 2024;24(2):e80-e81

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.

Marking U; Bladh O; Aguilera K; Yang Y; Greilert Norin N; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward DJ; Thålin C
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2023;389(17):1626-1628

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.

Bladh O; Greilert-Norin N; Havervall S; Marking U; Aguilera K; Alm JJ; Blom K; Åberg M; Klingström J; Thålin C
Letter: THE LANCET REGIONAL HEALTH - EUROPE. 2023;33:100725

Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden.

Blom K; Bladh O; Havervall S; Marking U; Greilert Norin N; Alm JJ; Klingström J; Thålin C
Letter: LANCET INFECTIOUS DISEASES. 2023;23(8):e272-e273

Mucosal IgA protects against BQ.1 and BQ.1.1 infection.

Marking U; Bladh O; Havervall S; Greilert-Norin N; Gordon M; Alm JJ; Blom K; Åberg M; Klingström J; Thålin C
Letter: LANCET MICROBE. 2023;4(7):e488

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose.

Bladh O; Marking U; Havervall S; Norin NG; Aguilera K; Hober S; Smed-Sörensen A; Gordon M; Blom K; Åberg M; Klingström J; Thålin C
Letter: LANCET INFECTIOUS DISEASES. 2023;23(2):150-152

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.

Marking U; Bladh O; Havervall S; Svensson J; Greilert-Norin N; Aguilera K; Kihlgren M; Salomonsson A-C; Månsson M; Gallini R; Kriegholm C; Bacchus P; Hober S; Gordon M; Blom K; Smed-Sörensen A; Åberg M; Klingström J; Thålin C
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2022;387(14):1333-1336

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.

Havervall S; Marking U; Svensson J; Greilert-Norin N; Bacchus P; Nilsson P; Hober S; Gordon M; Blom K; Klingström J; Åberg M; Smed-Sörensen A; Thålin C
Letter: EMERGING INFECTIOUS DISEASES. 2022;28(10):2119-2121

Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022.

Blom K; Havervall S; Marking U; Norin NG; Bacchus P; Groenheit R; Bråve A; Thålin C; Klingström J
Letter: LANCET INFECTIOUS DISEASES. 2022;22(7):943-945

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.

Blom K; Marking U; Havervall S; Norin NG; Gordon M; García M; Tecleab T; Christ W; Forsell M; Phillipson M; Nilsson P; Mangsbo S; Hober S; Åberg M; Klingström J; Thålin C
Letter: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2022;20(1):267-269

Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.

von Meijenfeldt FA; Havervall S; Adelmeijer J; Thalin C; Lisman T
Letter: THROMBOSIS AND HAEMOSTASIS. 2021;121(12):1668-1669

COVID-19 is Associated with an Acquired Factor XIII Deficiency.

von Meijenfeldt FA; Havervall S; Adelmeijer J; Lundström A; Magnusson M; Mackman N; Thalin C; Lisman T
Letter: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2021;41(6):e381-e382

Response by Mackman et al to Letter Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report".

Mackman N; Hisada Y; Grover SP; Rosell A; Havervall S; von Meijenfeldt F; Aguilera K; Lisman T; Thålin C
Letter: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2021;325(19):2015-2016

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers.

Havervall S; Rosell A; Phillipson M; Mangsbo SM; Nilsson P; Hober S; Thålin C
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(4):E98-E100

Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality.

von Meijenfeldt FA; Havervall S; Adelmeijer J; Lundström A; Magnusson M; Mackman N; Thalin C; Lisman T
Letter: BLOOD ADVANCES. 2021;5(3):756-759

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge.

von Meijenfeldt FA; Havervall S; Adelmeijer J; Lundström A; Magnusson M; Mackman N; Thalin C; Lisman T

About me

Articles

All other publications

News from KI

Events from KI